QTR-2 FINANCIAL RESULT
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rekvina Laboratories reported total income of Rs. 19.62 lacs for Q2 FY26, compared to nil in both Q1 FY26 and Q2 FY25, with a total of Rs. 19.62 lacs for H1 FY26. The company posted a loss after tax of Rs. 3.49 lacs for the quarter and Rs. 7.03 lacs for the half-year, though the quarterly loss narrowed from Rs. 6.65 lacs in Q2 FY25. The balance sheet remains deeply stressed, with negative total equity of Rs. 75.28 lacs because accumulated losses of Rs. 376.68 lacs exceed the share capital of Rs. 301.40 lacs. Borrowings have surged over threefold year-on-year to Rs. 81.23 lacs, while cash has collapsed to just Rs. 0.18 lacs and operating cash flow was negative at Rs. 23.85 lacs for H1 FY26. The statutory auditor (Y. M. Shah & Co.) issued an unqualified limited review report.
Persistent losses, a negative net worth, almost-depleted cash, and heavy reliance on new borrowings to fund operations point to serious going-concern and solvency risks for shareholders, even though the auditor raised no qualifications.